Introduction {#sec1-1}
============

Stroke is the collective name for cerebrovascular disease with brain functional deficits due to a number of causes. Stroke is associated with high morbidity, mortality, and disability rates, and is regarded as one of three major lethal diseases in most countries because of increasing morbidity and mortality (Bliss et al., 2007; Li et al., 2009). Stem cell transplantation offers a new avenue for stroke treatment, and has been used to treat stroke for the last 10 years (Kalluri et al., 2008). Stem cells are used to replace necrotic nerve tissue, and thereby contribute to neural network reconstruction through a number of mechanisms, including replacing necrotic neurons with new functional neurons, maintaining neural circuits and reconstructing neural conduction pathways by replacing necrotic glial cells, providing nutrients for tissue at the peri-infarct penumbra, and promoting survival, transfer, and differentiation of endogenous progenitors through neurotrophic factor secretion. After transplantation, both endogenous and exogenous neural stem cells migrate to the distal injury area and differentiate into new nerve cells, promoting tissue restoration and functional restoration in the central nervous system, particularly after cerebral infarction (Thored et al., 2006; Zheng et al., 2009). A variety of stem cells have been used in stroke treatment, including neural, bone marrow mesenchymal, umbilical cord blood, and embryonic stem cells (Darsalia et al., 2005; Liu, 2013). Although these stem cells are derived from different cell types, they share a similar theoretical basis in treatment of ischemic stroke, namely cell replacement, immunomodulation, neuroprotection, and neurotrophy, which contribute to relieving nerve damage and promoting functional recovery (Hasegawa et al., 2006; Sensebé et al., 2010). The mode of transplantation is one component of efficient stem cell transplantation for stroke treatment, and commonly used approaches involve direct, intravenous, or arterial injections. Moreover, the choice of stem cells (neural, bone marrow mesenchymal, umbilical cord blood or embryonic) is also key to stem cell transplantation (Darsalia et al., 2007). Efficacy of stroke treatment using stem cells is determined by the stem cell source, transplantation approach, stem cell survival and host integration, and treatment safety (Arvidsson et al., 2002; Ourednik et al., 2002), although many questions are unanswered: how can stem cell transplantation success in clinical practice be achieved in a safe and rapid manner based on current clinical trial results? And what are the mechanisms of action? Further efforts are needed to explore treatment profiles (Zhao et al., 2002; Kawai et al., 2010). In this study, we analyzed published literature on stroke stem cell transplantation by examining funded and registered studies.

Trends from Published Articles about Stem Cell Transplantation for Stroke Treatment {#sec1-2}
===================================================================================

Computer-based retrieval was performed using Thomson Reuters Web of Science database (<http://webofknowledge.com/>), the National Institutes of Health (NIH) Common Fund database (<http://www.nih.gov/>), and Clinical Trial Registration Center in North America (<http://www.clinicaltrials.gov/>), between 2004-01-01 and 2013-12-31. Key words used were "stem cell", "stroke", "transplantation", "neural stem cells", "mesenchymal stem cells", "bone marrow mesenchymal stem cells", "bone mesenchymal stem cells", "adipose-derived stem cells", "umbilical cord blood stem cells", and "embryonic stem cell".

Inclusion criteria {#sec2-1}
------------------

Any article about stem cell transplantation for stroke treatment was included.

Exclusion criteria {#sec2-2}
------------------

\(1\) Articles without the authors' approval; and (2) unpublished articles.

Literature analysis {#sec2-3}
-------------------

Included articles were quantitatively and qualitatively analyzed using the following categories: publication time, publication nation and region, article type, institution distribution, and publication sources. Analysis methods included retrieval from Web of Science and NIH Common Fund databases, analysis functions in the Clinical Trial Registration Center in North America, and graphics functions of Excel software. Article types included original research, reviews, conference abstracts, conference articles, editorials, and chapters.

Results {#sec1-3}
=======

Efficacy of stem cell transplantation for stroke treatment {#sec2-4}
----------------------------------------------------------

We initially compared the advantages and disadvantages of using different stem cell types for transplantation in stroke treatment (**[Table 1](#T1){ref-type="table"}**).

###### 

Different stem cell types for stroke treatment
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Literature analysis of the Web of Science database between 2004 and 2013 {#sec2-5}
------------------------------------------------------------------------

### Number of articles on different stem cell types for stroke treatment {#sec3-1}

Next, we determined the number of articles published in the Web of Science database between 2004 and 2013, on different types of stem cell transplantation for stroke treatment (**[Table 2](#T2){ref-type="table"}**).

###### 

Number of articles published on different types of stem cell transplantation for stroke treatment
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Of the included articles, those focusing on neural stem cell transplantation have sharply increased, followed by bone marrow stem cell transplantation. Articles about embryonic and umbilical cord blood stem cell transplantation do not show significant increases. In total, 2,617 related articles were assessed, including 87 articles published in 2004, 102 in 2005, 146 in 2006, 159 in 2007, 170 in 2008, 262 in 2009, 280 in 2010, 319 in 2011, 312 in 2012, and 388 in 2013. Therefore, the number of stroke treatment related articles published in the Web of Science database has increased within the last 5 years, with the maximum published in 2013.

### Highly cited articles on stem cell transplantation for stroke treatment {#sec3-2}

According to bibliometrics, citation frequency is the main indicator for determining literature quality and reflects the academic value of peer reviews, with higher citation frequencies indicating greater scientific value (Zhou et al., 2005; Yue et al., 2008). Thus, we determined highly cited articles from the 2,617 related articles identified from the Web of Science database between 2004 and 2013 (**[Table 3](#T3){ref-type="table"}**).

###### 

Highly cited articles on stem cell transplantation for stroke treatment
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### Analysis of publication countries {#sec3-3}

Publication countries of included articles identified from the Web of Science database between 2004 and 2013 were analyzed (**[Figure 1](#F1){ref-type="fig"}**).

![Top 9 countries publishing articles on stem cell transplantation for stroke treatment.](NRR-9-1643-g004){#F1}

Of the 2,167 published articles, the USA has published the most (854 articles, 39.4%), followed by China (361 articles), Japan (198 articles), Germany (173 articles), South Korea (157 articles), UK (120 articles), Canada (112 articles), and other countries (\< 100 articles) ([Figure 2](#F2){ref-type="fig"}). There are three Asian countries in the top nine, showing regional dominance in this research field.

![Top ten institutions publishing articles on stem cell transplantation for stroke treatment.\
I: Oakland University; II: Henry Ford Hospital; III: University of Flori-da; IV: Stanford University; V: The University of British Columbia; VI: Harvard University; VII: Yale University; VIII: Fudan University; IX: Ajou University; X: Medical College of Georgia.](NRR-9-1643-g005){#F2}

### Analysis of article type {#sec3-4}

The majority of articles published were original research (up to 1,535 articles, 70.8%), followed by reviews (395 articles, 18.3%), meeting abstracts (147 articles), and other types (\< 100 articles) (**[Table 4](#T4){ref-type="table"}**).

###### 

Types of published articles on stem cell transplantation for stroke treatment
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### Analysis of publication institutions {#sec3-5}

Publication institutions of included articles were analyzed (**[Figure 2](#F2){ref-type="fig"}**).

Of the top ten institutions publishing articles on stem cell transplantation for stroke treatment, Oakland University occupies first place (83 articles, 3.8%), followed by the Henry Ford Hospital (77 articles), University of Florida (68 articles), and Stanford University (63 articles). The majority of publication institutions are located in the USA, although Fudan University and Asia University are also ranked in the top ten.

### Analysis of publication journals {#sec3-6}

The majority of included articles were published in brain science journals, including *Stroke* (145 articles, 6.7%), *Brain Research* (72 articles), *Cell Transplantation* (70 articles), *Journal of Cerebral Blood Flow and Metabolism* (63 articles), *PLOS ONE* (57 articles), *Experimental Neurology* (51 articles), and other journals (\< 50 articles) (**[Table 5](#T5){ref-type="table"}**). Statistical analysis of publication journals enables researchers and physicians to identify key journals and determine relevant literature on stem cell transplantation for stroke treatment. In turn this will guide submission and improve acceptance rates, which is conducive to expanding research achievements.

###### 

Top ten journals publishing articles on stem cell transplantation for stroke treatment
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### Analysis of funding agencies {#sec3-7}

The funding agencies responsible for published articles were determined (**[Table 6](#T6){ref-type="table"}**).

###### 

Funding agencies responsible for published articles on stem cell transplantation for stroke treatment
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The majority of published articles were financially supported by NIH (143 articles, 6.6%), the National Natural Science Foundation of China (91 articles, 4.2%), and other agencies (\< 50 articles).

NIH-funded ongoing projects on stem cell transplantation for stroke treatment {#sec2-6}
-----------------------------------------------------------------------------

NIH not only conducts scientific research engaged in medical fields, but also provides major biomedical research funding to non-NIH research facilities, such as universities, medical colleges, hospitals, and other research institutions. In addition, NIH assists in staff training and promotes exchange of medical information.

During 2013--2014, NIH provided financial support for 329 ongoing research projects on stem cell transplantation in stroke treatment (**[Table 7](#T7){ref-type="table"}**), with total funding of over \$130 million. In 2014, 215 projects were newly approved, with funding of \$70,440,000 and an average project fund of \$328,000. Of the 329 NIH-funded research projects, 141 articles were financially supported by the National Institute of Neurological Disorders and Stroke, with up to \$58,700,000 of subsidy and an average project fund of \$416,000. The NIH Heart, Lung, and Blood Institute was second, with total funds of up to \$15,020,000.

###### 

Number of ongoing NIH projects and funding for stem cell transplantation in stroke treatment
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Analysis of the Clinical Trial Registration Program in North America {#sec2-7}
--------------------------------------------------------------------

The North American Clinical Trial Data Center (<http://www.clinicaltrials.gov/>) was jointly developed by the NIH, National Library of Medicine (NLM), and United States Food and Drug Administration (FDA) in February 2000. The aim of the North American Clinical Trial Data Center is to report in a timely manner, clinical trial information sponsored by NIH, other National Government Agencies, and the American Medical Association, and provide related services for patients and their families, medical staff and the public. As stipulated by NIH, any clinical trial targeting experimental treatments for serious or life-threatening diseases and conditions are registered, regardless of funding is provided nationally or privately. Registration aims to share progress of all world-wide clinical trials through the internet.

The North American Clinical Trial Data Center includes nearly 180,000 clinical trials funded by NIH, other federal government agencies, and private enterprises, and receives \> 50 million page views per month and \> 65,000 visitors per day. Of all registered clinical trials, 52,381 projects were from the USA (accounting for 51%), while over 7,000 clinical trials were registered by Chinese researchers. Registration areas for clinical trials on stem cell transplantation for stroke treatment are shown (**[Table 8](#T8){ref-type="table"}**).

###### 

Regions of registered clinical trials on stem cell transplantation for stroke treatment in the North American Clinical Trial Data Center
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Ninety clinical trials are registered in the North American Clinical Trial Data Center. Of these, 40 projects are registered in North America (ranked first place), followed by Europe, with the UK responsible for seven projects, France six, Germany six, and Spain four. In Asia, China has the most ongoing research projects or completed clinical trials (*n* = 10).

Discussion {#sec1-4}
==========

In the past 10 years, an increasing amount of literature has highlighted the use of stem cell transplantation for stroke treatment. In 2008, only 87 articles were published, increasing to 388 in 2013. Different stem cell types have been widely applied for stroke treatment, with a sharp increase in the number of studies addressing neural stem cell transplantation, followed by bone marrow mesenchymal stem cell transplantation. Embryonic and umbilical cord blood stem cell transplantation are rarely documented, showing no significant increase in number of related studies.

We found that from 2004--2013, the USA is the most SCI-indexed country for articles on stem cell transplantation for stroke treatment, publishing the most literature and highlighting the contribution of this country to medical research in the stroke field. China ranks second, publishing 292 articles. The top publication institutions for articles are Oakland University, Henry Ford Hospital, and University of Florida, all located in the USA. Knowledge of key institutions for stem cell transplantation will facilitate technical exchange and research cooperation among experts.

Of the funding agencies responsible for supporting projects on stem cell transplantation for stroke treatment, NIH provides financial support for 143 articles (accounting for 6.6% of total literature), while the National Natural Science Foundation of China funded 91 articles, demonstrating China\'s contribution to the field of stem cell transplantation.

At present, NIH provides considerable funds for medical research addressing stem cell transplantation for stroke treatment, funding 329 ongoing projects with over \$130 million of total subsidy.

Among the 90 clinical trials registered in the North America Clinical Trial Data Center, 40 projects were registered in North America (occupying first place), followed by Europe with UK (7 projects), France (6 projects), Germany (6 projects), and Spain (4 projects). In Asia, China has the maximum ongoing research or completed clinical trials (10 projects).

In recent years, stem cell transplantation has become a hot spot for stroke treatment, but its clinical application has been greatly restricted (Buchan et al., 2001; Pollock et al., 2006). Further work is needed to determine a stem cell source, transplantation approach, safety of cell transplantation, therapeutic time window, therapeutic dose, route of administration, choice of cell lines, indications, long-term effects and risk assessment, stem cell survival and integration in the host (Nelson et al., 2002; Chu et al., 2004). Currently, there is no strong evidence showing that transplanted stem cells can replace damaged cells, reconstruct neural circuits, or improve loss of function after stroke (Fan et al., 2010; Darsalia et al., 2011), and many questions remain. For example, how can neurological recovery in transplant recipients be promoted, and how can tumorigenicity, pathogenicity, and immune rejection of transplanted stem cells be detected? (Bühnemann et al., 2006; Hacke et al., 2008). Resolution of these problems will allow broader application of neural stem cell transplantation.
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